🇺🇸 FDA
Patent

US 11118183

Modulation of angiopoietin-like 3 expression

granted A61PA61P3/00A61P3/04

Quick answer

US patent 11118183 (Modulation of angiopoietin-like 3 expression) held by Ionis Pharmaceuticals, Inc. expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P3/00, A61P3/04, A61P43/00, A61P9/00